U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Cefiderocol Injection
  1. Development Resources

Cefiderocol Injection

FDA Identified Breakpoints

 

Minimum Inhibitory Concentrations (mcg/mL)

Disk Diffusion (zone diameters in mm)

Pathogen

S

I

R

S

I

R

Enterobacteralesa,b

M-100 standard is recognized

Pseudomonas aeruginosa

≤1

2

≥ 4

≥22

13-21

≤12

Acinetobacter baumannii complex

≤1

2

≥ 4

≥19

12-18

≤11

Stenotrophomonas maltophilia

M-100 standard is recognized

≥17

-

-

aClinical efficacy was shown for Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae complex in patients with complicated urinary tract infections (cUTI).

bClinical efficacy was shown for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae complex, and Serratia marcescens in patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

S = Susceptible; I = Intermediate; R = Resistant
For disk diffusion, use paper disks impregnated with 30 mcg cefiderocol.

Back to Top